


AGGREGATE TOTAL RAISED PER ROUND | AVG. ROUND SIZE (US \$M)



OnBioVC tracked 31 financings for Nov. '08, up 6 from 25 in Oct. '08. The month combined proceeds totaled approximately \$652M, bringing aggregate '08 YTD institutional bioscience venture investments to approximately \$5.9B. The composite average deal size for the eleventh month of '08 was \$32M. Diagnostics continue to be the sector where investment dollars are concentrated, five deals in Oct. totaling \$71M raised was followed by three deals in Nov. totaling \$57M raised.

The largest deal of the month was OncoMed Pharma, focused on cancer stem cell therapeutics the company closed on the final \$93M tranche of its \$154M Series B financing. Similarly, Pacira a specialty pharma company with an approved product for post-op pain, added the final \$55M tranche to close out its Series A financing at \$85M.

The North East region put together back-to-back months of leadership in both the number of financings closed (7 in Oct. and 8 in Nov.) and dollars raised (\$164M in Oct. and \$205M in Nov.). The next most active region was the West region with 9 financings accounting for \$173M raised.

COMPAY FOCI	# of Financings
Device (Diagnostic)	3
Stem Cell	2
Therapeutic Platform	2
Allergy	1
ALS	1
Alzheimer's	1
Anemia	1
Antibody	1
Antiinfective	1
Antiviral	1
Bioagriculture	1
Cardiovascular	1
CMO	1
CNS	1
Dermatology	1
Device (Cardiology)	1
Device (IVF)	1
Device (Vascular)	1
G Protein	1
GI	1
Immunology	1
Injectable	1
Oncology	1
Osteoporosis	1
RA	1
Screening	1
Stealth Mode	1

Information contained herein is based on sources the Company believed reliable at time of reporting but is not guaranteed by the Company or its subsidiaries and is not considered all inclusive, no representation is made to accuracy or completeness, and it should not be relied on as such. OnBioVC is not acting in any fiduciary capacity. © 2008 Indiciu Data, LLC. Some rights reserved.

## ONBIOVC.com TREND ANALYSIS


### NOVEMBER 2008

COMPANY	ROUND	RAISE (\$M)	REGION	1° INDICATION	2° INDICATION
Accera	C	35.0	Rocky Mountain	Alzheimer's	Medical Food
AnaMar Medical	B	9.3	International	RA	
Arete Therapeutics	A	16.7	West	Cardiovascular	Metabolic
Argos Therapeutics	C	32.5	South East	Immunology	Oncology
Ascent Therapeutics	A	19.0	North East	G Protein	
Cebix	A	2.9	West	Stealth Mode	
Cellular Dynamics	A	18.0	Mid West	Screening	Stem Cell
Chiral Quest	B	13.0	North East	CMO	
Chromatin	C	12.6	Mid West	Bioagriculture	
Cogentus Pharmaceuticals	C	22.5	West	GI	Cardiovascular
Evogen	B	3.0	Mid West	Device (Diagnostic)	
FerroKin Biosciences	A	15.0	West	Anemia	
GangaGen	E	5.4	West	Antiinfective	Bacteriophage
Ganymed Pharmaceuticals	D	82.0	International	Antibody	Oncology
Jado Technologies	B	4.9	International	Allergy	Antiinfective
Knopp Neurosciences	B	27.0	North East	ALS	CNS
MicroPhage	A	11.0	Rocky Mountain	Device (Diagnostic)	Bacteriophage
Molecular Biometrics	A	12.0	North East	Device (IVF)	
Nanostim	A	9.7	West	Device (Cardiology)	
Numerate	A	4.0	West	Therapeutic Platform	
Okapi Sciences	A	10.8	International	Antiviral	Veterinary
OncoMed Pharmaceuticals	B	93.0	West	Stem Cell	Oncology
Pacira Pharmaceuticals	A	55.0	North East	Injectable	Deliver
Precision Therapeutics	F	43.0	North East	Device (Diagnostic)	Oncology
Prolexys Pharmaceuticals	A	20.0	Rocky Mountain	Oncology	Cardiovascular
Psyadon Pharmaceuticals	A	8.0	Mid Atlantic	CNS	
Radius Health	C	15.0	North East	Osteoporosis	Endometriosis
Sol-Gel Technologies	B	9.0	International	Dermatology	
Tactile Systems	A	15.8	Mid West	Device (Vascular)	Lymphedema
Tengion	C	21.0	North East	Stem Cell	
Zacharon Pharmaceuticals	A	3.5	West	Therapeutic Platform	Glycan


Based in Boulder, Colorado, OnBioVC provides timely coverage and comprehensive analysis of global bioscience venture capital investment activity.  
[www.OnBioVC.com](http://www.OnBioVC.com)

## NOVEMBER 2008 ONBIOVC.com TREND ANALYSIS

### AGGREGATE TOTAL RAISED PER REGION | AVG. ROUND SIZE (US \$M)




### FINANCINGS BY ROUNDS




# NOVEMBER 2008 ONBIOVC.com TREND ANALYSIS

## YTD \$ RAISED | YTD FINANCING ROUND

Series A Series B Series C Series D Series E Series F Series G TOTAL




## Deal Tracker by Month and Financing Round



## NOVEMBER 2008 ONBIOVC.com TREND ANALYSIS

### ONBIOVC-INDEX™ vs. NASDAQ Biotech Index vs. Dow Jones Industrial Average



Following a highly correlated September and October, the OnBioVC-Index™ experienced an uncanny outperformance of the Nasdaq Biotech Index on a relative basis by approximately 230bps and the broader DJIA Index by nearly 350bps. Though the public markets are in the midst of a tumultuous period, the financial crisis of September & October and continued slide throughout November does not appear to be reflected in the eleventh month of bioscience venture capital investment levels.

**PARTNERS**



Modeled after successful medical research parks across the country, the Colorado Science + Technology Park at [Fitzsimons](#) offers an unrivaled range of opportunity to life science research and development companies of all sizes, from small start-ups to established industry leaders. Within the Park, more than six million square feet of corporate and bioresearch facility space are being developed for companies and firms focusing on the science and technology sectors.

From cutting-edge lab facilities to advanced technical support systems, everything at the Colorado Science + Technology Park at Fitzsimons is designed specifically for the life science industry - turnkey solutions are currently available. It's a place where the best and brightest will come together to take ideas from the bench to bedside; a place where creativity and collaboration reach critical mass.

Forest City Science + Technology Group is a division of Forest City Enterprises, a national real estate development firm founded more than 80 years ago and traded on the New York Stock Exchange. Forest City creates award-winning communities for people to live, work, and play.

The Science + Technology Group, recognized as one of the country's premiere developers of life science campuses, has a completed portfolio of over two million square feet and more than 5 million square feet of wet-lab and office space under development in several major US life science markets including Boston, Philadelphia, Baltimore, Chicago, and Denver.

Forest City Science + Technology Group has the vision, practical experience, and the capabilities to design, build, lease, fit out, finance, operate, and meet the complex needs of each client - from early stage to mature organizations.



**Contact + Leasing + Business Development**

**Colorado Science + Technology Park at [Fitzsimons](#)**  
7351 E. 29th Avenue Denver, CO 80238  
Call 720.941.7100 or visit [www.FitzScience.com](http://www.FitzScience.com)

PARTNERS

**THE  
CBSA  
ADVANTAGE**

---



**The BioScience Industry in Colorado**

Colorado's bioscience industry is poised to become one of the most exciting and advanced clusters in the country. The State is currently home to a thriving industry, comprised of over 400 biotechnology, medical device, pharmaceutical, health care providers, research institutions and those businesses that provide critical services and products to bioscience companies.

**Opportunities for Growth in the Biosciences Industry**

The pipeline of new technologies and new companies emerging from Colorado's research institutions is strong; the number of Colorado bioscience related companies and their employees are growing faster than the national average. At the center of this exciting growth is the Colorado Bioscience Association (CBSA), shaping the policies and developing the programs to help Colorado's companies grow and prosper.

**Become a Part of this World Class Bioscience Cluster.  
Join the CBSA. For More Information Visit:  
[www. CoBioScience.com](http://www.CoBioScience.com)**

PARTNERS



## ABOUT

### **OnBioVC provides timely coverage and comprehensive analysis of global bioscience venture capital investment activity.**

At OnBioVC a free and easy to search database is provided where information queries may be indexed by therapeutic, diagnostic and medical device company, technology, indication, financing-round, close date and geographic region. In addition to the web-based resource, regularly published OnBioVC Trend Analysis studies provide cumulative analytical color by month and quarter. All data aggregated at OnBioVC is also available for delivery to your inbox via a free email or RSS subscription.

For Advertising Inquiries Contact:

advertise@onbiovc.com

**303.902.4413**

www.**OnBioVC**.com

© 2008 Indicium Data, LLC. Some rights reserved.